PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25825724-0	2015	ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.	Adenosine Triphosphate	0-3	Janus kinase 2	Mus musculus	42-46	
25825724-4	2015	JH2 of JAK1, JAK2, and TYK2 all bind ATP, but the significance of this is unclear.	Adenosine Triphosphate	37-40	immunoglobulin heavy variable 1-53	Mus musculus	0-3	
25825724-4	2015	JH2 of JAK1, JAK2, and TYK2 all bind ATP, but the significance of this is unclear.	Adenosine Triphosphate	37-40	Janus kinase 1	Mus musculus	7-11	
25825724-4	2015	JH2 of JAK1, JAK2, and TYK2 all bind ATP, but the significance of this is unclear.	Adenosine Triphosphate	37-40	Janus kinase 2	Mus musculus	13-17	
25825724-4	2015	JH2 of JAK1, JAK2, and TYK2 all bind ATP, but the significance of this is unclear.	Adenosine Triphosphate	37-40	tyrosine kinase 2	Mus musculus	23-27	
25825724-6	2015	Disruption of JH2 ATP binding in wild-type JAK2 has only minor effects, and in the presence of type I cytokine receptors, the mutations do not affect JAK2 activation.	Adenosine Triphosphate	18-21	immunoglobulin heavy variable 1-53	Mus musculus	14-17	
25825724-6	2015	Disruption of JH2 ATP binding in wild-type JAK2 has only minor effects, and in the presence of type I cytokine receptors, the mutations do not affect JAK2 activation.	Adenosine Triphosphate	18-21	Janus kinase 2	Mus musculus	43-47	
25825724-7	2015	However, JH2 mutants devoid of ATP binding ameliorate the hyperactivation of JAK2 V617F.	Adenosine Triphosphate	31-34	immunoglobulin heavy variable 1-53	Mus musculus	9-12	
25825724-7	2015	However, JH2 mutants devoid of ATP binding ameliorate the hyperactivation of JAK2 V617F.	Adenosine Triphosphate	31-34	Janus kinase 2	Mus musculus	77-81	
25825724-8	2015	Disrupting ATP binding in JH2 also inhibits the hyperactivity of other pathogenic JAK2 mutants, as well as of JAK1 V658F, and prevents induction of erythrocytosis in a JAK2 V617F myeloproliferative neoplasm mouse model.	Adenosine Triphosphate	11-14	immunoglobulin heavy variable 1-53	Mus musculus	26-29	
25825724-8	2015	Disrupting ATP binding in JH2 also inhibits the hyperactivity of other pathogenic JAK2 mutants, as well as of JAK1 V658F, and prevents induction of erythrocytosis in a JAK2 V617F myeloproliferative neoplasm mouse model.	Adenosine Triphosphate	11-14	Janus kinase 2	Mus musculus	82-86	
25825724-8	2015	Disrupting ATP binding in JH2 also inhibits the hyperactivity of other pathogenic JAK2 mutants, as well as of JAK1 V658F, and prevents induction of erythrocytosis in a JAK2 V617F myeloproliferative neoplasm mouse model.	Adenosine Triphosphate	11-14	Janus kinase 1	Mus musculus	110-114	
25825724-8	2015	Disrupting ATP binding in JH2 also inhibits the hyperactivity of other pathogenic JAK2 mutants, as well as of JAK1 V658F, and prevents induction of erythrocytosis in a JAK2 V617F myeloproliferative neoplasm mouse model.	Adenosine Triphosphate	11-14	Janus kinase 2	Mus musculus	168-172	
25825724-9	2015	Molecular dynamic simulations and thermal-shift analysis indicate that ATP binding stabilizes JH2, with a pronounced effect on the C helix region, which plays a critical role in pathogenic activation of JAK2.	Adenosine Triphosphate	71-74	immunoglobulin heavy variable 1-53	Mus musculus	94-97	
25825724-9	2015	Molecular dynamic simulations and thermal-shift analysis indicate that ATP binding stabilizes JH2, with a pronounced effect on the C helix region, which plays a critical role in pathogenic activation of JAK2.	Adenosine Triphosphate	71-74	Janus kinase 2	Mus musculus	203-207	
25825724-10	2015	Taken together, our results suggest that ATP binding to JH2 serves a structural role in JAKs, which is required for aberrant activity of pathogenic JAK mutants.	Adenosine Triphosphate	41-44	immunoglobulin heavy variable 1-53	Mus musculus	56-59	
25825724-10	2015	Taken together, our results suggest that ATP binding to JH2 serves a structural role in JAKs, which is required for aberrant activity of pathogenic JAK mutants.	Adenosine Triphosphate	41-44	Janus kinase 1	Mus musculus	88-92	
25825724-11	2015	The inhibitory effect of abrogating JH2 ATP binding in pathogenic JAK mutants may warrant novel therapeutic approaches.	Adenosine Triphosphate	40-43	immunoglobulin heavy variable 1-53	Mus musculus	36-39